DOCSLIB.ORG

Ephrin-A1 Expression Contributes to the Malignant Characteristics of A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

843 HEPATOBILIARY DISEASE Ephrin-A1 expression contributes to the malignant Gut: first published as 10.1136/gut.2004.049486 on 11 May 2005. Downloaded from characteristics of a-fetoprotein producing hepatocellular carcinoma H Iida, M Honda, H F Kawai, T Yamashita, Y Shirota, B-C Wang, H Miao, S Kaneko ............................................................................................................................... Gut 2005;54:843–851. doi: 10.1136/gut.2004.049486 Background and aims: a-Fetoprotein (AFP), a tumour marker for hepatocellular carcinoma (HCC), is associated with poor prognosis. Using cDNA microarray analysis, we previously found that ephrin-A1, an angiogenic factor, is the most differentially overexpressed gene in AFP producing hepatoma cell lines. In the present study, we investigated the significance of ephrin-A1 expression in HCC. See end of article for Methods: We examined ephrin-A1 expression and its effect on cell proliferation and gene expression in authors’ affiliations five AFP producing hepatoma cell lines, three AFP negative hepatoma cell lines, and 20 human HCC ....................... specimens. Correspondence to: Results: Ephrin-A1 expression levels were lowest in normal liver tissue, elevated in cirrhotic tissue, and Dr S Kaneko, Department further elevated in HCC specimens. Ephrin-A1 expression was strongly correlated with AFP expression of Cancer Gene (r = 0.866). We showed that ephrin-A1 induced expression of AFP. This finding implicates ephrin-A1 in Regulation, Kanazawa University Graduate the mechanism of AFP induction in HCC. Ephrin-A1 promoted the proliferation of ephrin-A1 School of Medical Science, underexpressing HLE cells, and an ephrin-A1 antisense oligonucleotide inhibited the proliferation of 13-1 Takara-Machi, ephrin-A1 overexpressing Huh7 cells. Thus ephrin-A1 affects hepatoma cell growth. cDNA microarray Kanazawa, 920-8641, Japan; skaneko@ analysis showed that ephrin-A1 induced expression of genes related to the cell cycle (p21), angiogenesis medf.m.kanazawa-u.ac.jp (angiopoietin 1 and thrombospondin 1), and cell-cell interactions (Rho, integrin, and matrix metalloproteinases) in cultured hepatoma cells. These ephrin-A1 induced genes are also activated in Revised version received HCC tissues that overexpress AFP. 26 December 2004 Accepted for publication Conclusion: These findings suggest that the poor prognosis of patients with AFP producing HCC is partially 11 January 2005 caused by ephrin-A1 expression, which induces expression of genes related to tumour cell growth, ....................... angiogenesis, invasion, and metastasis. http://gut.bmj.com/ lpha-fetoprotein (AFP), a tumour marker for hepato- participates in tumorigenesis, the biological significance and cellular carcinoma (HCC), is expressed in fetal liver but expression pattern of ephrin-A1 in HCC are unknown. Ais not expressed in normal adult liver. Approximately In the present study, we investigated ephrin-A1 expression 70% of HCCs are positive for AFP, and levels of AFP increase in HCC specimens and hepatoma cell lines, and we examined with tumour progression.1 HCCs with high levels of AFP have the effect of ephrin-A1 on cell proliferation and gene a poor prognosis and exhibit multicentric growth more expression. We also discuss the significance of ephrin-A1 frequently than AFP negative HCCs.2–4 In a previous study, expression in AFP producing HCC. on October 2, 2021 by guest. Protected copyright. we identified a gene cluster that was characteristically expressed in AFP producing hepatoma cell lines but not in MATERIALS AND METHODS non-AFP producing hepatoma cell lines.5 In this cluster, Cell lines ephrin-A1 was the most differentially overexpressed gene in Huh7, Hep3B, HepG2, Huh6, PLC/PRF/5, SK-Hep1, and HLE AFP producing hepatoma cell lines. cells were maintained in Dulbecco’s modified Eagle’s Ephrin-A1, a ligand for the Eph receptor tyrosine kinase, is medium supplemented with 10% fetal bovine serum. The involved in vascular development, tissue border formation, simian virus 40 large-T antigen-immortalised normal cell migration, axon guidance, synaptic plasticity, and adult human hepatocyte cell line (THLE-5b) was maintained in neovascularisation.6 Several lines of evidence suggest that PMFR-4.13 14 ephrin-A1 plays roles in multiple aspects of tumorigenesis, including abnormal cell growth, angiogenesis, invasion, and Tissue specimens metastasis.7–12 Overexpression of ephrin-A1 in melanoma Cancerous and non-cancerous tissues were obtained from cells correlates with an increase in tumour cell growth, patients who underwent partial hepatectomy for HCC. indicating that ephrin-A1 acts as a cell survival factor or a Normal controls were histologically normal tissues and were promoter of abnormal cell growth in tumour cells.9–11 Ephrin- obtained from patients who underwent partial hepatectomy A1 and its receptor are consistently expressed in endothelial for metastatic liver tumours. These patients had no obvious cells of tumour associated vessels in a variety of human underlying disease, tested negative for all hepatitis virus tumours, including lung, stomach, and colorectal cancers,7 markers, and had normal levels of serum transaminase. and blocking the EphA receptor inhibits tumour angiogenesis and tumour progression in vivo.8 Inappropriate expression Abbreviations: AFP, a-fetoprotein; HCC, hepatocellular carcinoma; and regulation of ephrin ligands and Eph receptors affects RIA, radioimmunoassay; IGF-II, insulin-like growth factor II; TGF-b, 12 transforming growth factor b; BMP, bone morphogenetic protein; TSP-1, cell-matrix interaction by modulating integrin activity. thrombospondin 1; MMP-2, matrix metalloproteinase 2; SDS-PAGE, Although these findings suggest that ephrin-A1 expression sodium dodecyl sulphate-polyacrylamide gel electrophoresis www.gutjnl.com 844 Iida, Honda, Kawai, et al incubated overnight at 4˚C with anti-ephrin-A1 (Santa Cruz AFP Biotechnology, Santa Cruz, California, USA), anti-EphA1 (R&D Systems, Minneapolis, Minnesota, USA), or anti-AFP 2.01 0.98 1.23 1.01 0.88 0.06 0.08 0.06 antibodies (DakoCytomation, Glostrup, Denmark), and were Gut: first published as 10.1136/gut.2004.049486 on 11 May 2005. Downloaded from subjected to the ABC immunostaining procedure using a Ephrin-A1 Vectorstain ABC kit (Vector, Burlingame, California, USA), followed by DAB (Sigma-Aldrich Co., S. Louis, Missouri, 1.39 1.41 0.98 1.47 1.39 0.10 0.09 0.08 USA). Negative controls were normal liver tissues in which northern blotting and western blotting confirmed the β-actin absence of ephrin-A1, AFP, and EphA1 expression. HLE Antisense-oligodeoxynucleotide and cell proliferation Huh7 Huh6 Hep3B HepG2 SK-Hep1 THLE-5b assay PLC/PRF/5 We designed an antisense phosphorothioate oligodeoxy- nucleotide (59-CCA GAG GAA CTC CAT AGC GC-39) Figure 1 Expression of a-fetoprotein (AFP) and ephrin-A1 mRNA in complementary to the ephrin-A1 gene nucleotide sequence eight human hepatoma cell lines determined by northern blotting (20 mg RNA/lane). Expression levels of AFP and ephrin-A1 mRNA were that spans from five nucleotides upstream of the predicted quantified. The ratio of AFP or ephrin-A1 to b-actin is shown below each translational initiation site to 15 nucleotides downstream northern blot. from this site. We also used a sense oligodeoxynucleotide (59- GCG CTA TGG AGT TCC TCT GG-39) as a negative control. Cancerous and non-cancerous tissues were separately enu- For positive controls, we used an antisense oligodeoxy- cleated from resected tissues and were then immediately nucleotide for the potent HCC growth factor, insulin-like frozen in liquid nitrogen. Histological characterisation of HCC growth factor II (IGF-II; 59-TCT GCC TCG CAG TTG G-39), and normal liver tissue was performed as described pre- and its control sense oligodeoxynucleotide (59-TGT CTC CCA 17 3 viously.15 16 Informed consent was obtained from all patients GGC GGT T-39). For the proliferation assay, 3610 cells and ethics approval for the study was obtained from the were cultured in 96 well plates for 24 hours. Various ethics committee for human genome/gene analysis research concentrations of oligodeoxynucleotides were then added to at Kanazawa University Graduate School of Medical Science. the medium using the FuGENE6 transfection reagent (Boehringer Mannheim, Mannheim, Germany), and cultures were incubated for 72 hours. Cell growth was measured Northern blotting using the MTS assay kit (Promega, Madison, Wisconsin, Total RNA was isolated from cultured cells and frozen tissues USA). using a ToTally-RNA kit (Ambion, Austin, Texas, USA). Northern blotting was performed using a NorthernMax kit (Ambion). cDNA probes containing unique sequences from Clonal growth assay human AFP, ephrin-A1, EphA1, EphA2, p21WAF1/CIP1, thrombo- For studies using soluble ephrin-A1-Fc, 250 cells were plated spondin 1 (TSP-1), matrix metalloproteinase 2 (MMP-2), and in triplicate directly onto 12 well cell culture dishes in the b-actin were labelled with [a32P] dCTP by random presence of 0.3 mg/ml ephrin-A1-Fc. The medium was http://gut.bmj.com/ priming. mRNA expression levels were quantified with a changed every two days. After 8–10 days of culture, cell Fujix-MacBas1000 Bio-imaging analyser (Fujix, Tokyo, Japan). growth was measured using the MTS assay kit (Promega). Immunohistochemistry Ligand stimulation and cDNA microarray analysis Tissue specimens were fixed in 10% formalin, embedded in Subconfluent HLE cells were cultured with or without 1 mg/ paraffin blocks, and cut
Recommended publications
  • Ephrin-A Binding and Epha Receptor Expression Delineate the Matrix Compartment of the Striatum

    Ephrin-A Binding and Epha Receptor Expression Delineate the Matrix Compartment of the Striatum

    The Journal of Neuroscience, June 15, 1999, 19(12):4962–4971 Ephrin-A Binding and EphA Receptor Expression Delineate the Matrix Compartment of the Striatum L. Scott Janis, Robert M. Cassidy, and Lawrence F. Kromer Department of Cell Biology and Interdisciplinary Program in Neuroscience, Georgetown University Medical Center, Washington, DC 20007 The striatum integrates limbic and neocortical inputs to regulate matrix neurons. In situ hybridization for EphA RTKs reveals that sensorimotor and psychomotor behaviors. This function is de- the two different ligand binding patterns strictly match pendent on the segregation of striatal projection neurons into the mRNA expression patterns of EphA4 and EphA7. anatomical and functional components, such as the striosome Ligand–receptor binding assays indicate that ephrin-A1 and and matrix compartments. In the present study the association ephrin-A4 selectively bind EphA4 but not EphA7 in the lysates of ephrin-A cell surface ligands and EphA receptor tyrosine of striatal tissue. Conversely, ephrin-A2, ephrin-A3, and kinases (RTKs) with the organization of these compartments ephrin-A5 bind EphA7 but not EphA4. These observations im- was determined in postnatal rats. Ephrin-A1 and ephrin-A4 plicate selective interactions between ephrin-A molecules and selectively bind to EphA receptors on neurons restricted to the EphA RTKs as potential mechanisms for regulating the com- matrix compartment. Binding is absent from the striosomes, partmental organization of the striatum. which were identified by m-opioid
  • Inhibition of Metastasis by HEXIM1 Through Effects on Cell Invasion and Angiogenesis

    Inhibition of Metastasis by HEXIM1 Through Effects on Cell Invasion and Angiogenesis

    Oncogene (2013) 32, 3829–3839 & 2013 Macmillan Publishers Limited All rights reserved 0950-9232/13 www.nature.com/onc ORIGINAL ARTICLE Inhibition of metastasis by HEXIM1 through effects on cell invasion and angiogenesis W Ketchart1, KM Smith2, T Krupka3, BM Wittmann1,7,YHu1, PA Rayman4, YQ Doughman1, JM Albert5, X Bai6, JH Finke4,YXu2, AA Exner3 and MM Montano1 We report on the role of hexamethylene-bis-acetamide-inducible protein 1 (HEXIM1) as an inhibitor of metastasis. HEXIM1 expression is decreased in human metastatic breast cancers when compared with matched primary breast tumors. Similarly we observed decreased expression of HEXIM1 in lung metastasis when compared with primary mammary tumors in a mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse. Re-expression of HEXIM1 (through transgene expression or localized delivery of a small molecule inducer of HEXIM1 expression, hexamethylene-bis-acetamide) in PyMT mice resulted in inhibition of metastasis to the lung. Our present studies indicate that HEXIM1 downregulation of HIF-1a protein allows not only for inhibition of vascular endothelial growth factor-regulated angiogenesis, but also for inhibition of compensatory pro- angiogenic pathways and recruitment of bone marrow-derived cells (BMDCs). Another novel finding is that HEXIM1 inhibits cell migration and invasion that can be partly attributed to decreased membrane localization of the 67 kDa laminin receptor, 67LR, and inhibition of the functional interaction of 67LR with laminin. Thus, HEXIM1 re-expression in breast cancer has therapeutic advantages by simultaneously targeting more than one pathway involved in angiogenesis and metastasis. Our results also support the potential for HEXIM1 to indirectly act on multiple cell types to suppress metastatic cancer.
  • Rabbit Anti-Ephrin-A1 Rabbit Anti-Ephrin-A1

    Rabbit Anti-Ephrin-A1 Rabbit Anti-Ephrin-A1

    Qty: 100 µg/400 µl Rabbit anti-ephrin-A1 Catalog No. 34-3300 Lot No. See product label Rabbit anti-ephrin-A1 FORM This polyclonal antibody is supplied as a 400 µl aliquot at a concentration of 0.25 mg/ml in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide. The antibody is epitope-affinity-purified from rabbit antiserum. PAD: ZMD.39 IMMUNOGEN Synthetic peptide derived from the C-terminal end of mouse ephrin-A1 protein. SPECIFICITY This antibody is specific for the ephrin-A1 protein. REACTIVITY Reactivity is confirmed with a chimeric protein consisting of the extracellular domain of mouse ephrin-A1 and the Fc region of human IgG1. Cross-reactivity with human ephrin-A1 is confirmed with IHC experiments on human tissue sections and this reactivity was expected because of the 85% shared amino acid identity in the extracellular domain. Sample Western Immunoprecipitation Immunohistochemistry Blotting (FFPE) Mouse +++ +++ NT Human NT NT ++ (Excellent +++, Good++, Poor +, No reactivity 0, Not tested NT) USAGE Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. Western Blotting: 1-5 µg/mL Immunoprecipitation: 5-10 µg/ IP reaction Immunohistochemistry: 4-10 µg/mL Please note that immunohistochemical assays were optimized on formalin-fixed, paraffin-embedded tissue sections and Heat Induced Epitope Retrieval (HIER) with EDTA, pH 8.0 was required for optimal staining.
  • Eph Receptor Signalling: from Catalytic to Non-Catalytic Functions

    Eph Receptor Signalling: from Catalytic to Non-Catalytic Functions

    Oncogene (2019) 38:6567–6584 https://doi.org/10.1038/s41388-019-0931-2 REVIEW ARTICLE Eph receptor signalling: from catalytic to non-catalytic functions 1,2 1,2 3 1,2 1,2 Lung-Yu Liang ● Onisha Patel ● Peter W. Janes ● James M. Murphy ● Isabelle S. Lucet Received: 20 March 2019 / Revised: 23 July 2019 / Accepted: 24 July 2019 / Published online: 12 August 2019 © The Author(s) 2019. This article is published with open access Abstract Eph receptors, the largest subfamily of receptor tyrosine kinases, are linked with proliferative disease, such as cancer, as a result of their deregulated expression or mutation. Unlike other tyrosine kinases that have been clinically targeted, the development of therapeutics against Eph receptors remains at a relatively early stage. The major reason is the limited understanding on the Eph receptor regulatory mechanisms at a molecular level. The complexity in understanding Eph signalling in cells arises due to following reasons: (1) Eph receptors comprise 14 members, two of which are pseudokinases, EphA10 and EphB6, with relatively uncharacterised function; (2) activation of Eph receptors results in dimerisation, oligomerisation and formation of clustered signalling centres at the plasma membrane, which can comprise different combinations of Eph receptors, leading to diverse downstream signalling outputs; (3) the non-catalytic functions of Eph receptors have been overlooked. This review provides a structural perspective of the intricate molecular mechanisms that 1234567890();,: 1234567890();,: drive Eph receptor signalling, and investigates the contribution of intra- and inter-molecular interactions between Eph receptors intracellular domains and their major binding partners. We focus on the non-catalytic functions of Eph receptors with relevance to cancer, which are further substantiated by exploring the role of the two pseudokinase Eph receptors, EphA10 and EphB6.
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0052982 A1 Cohen Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2016/0052982 A1 Cohen Et Al

    US 2016.0052982A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0052982 A1 Cohen et al. (43) Pub. Date: Feb. 25, 2016 (54) METHODS AND SYSTEMIS FOR DESIGNING Related U.S. Application Data AND/OR CHARACTERIZING SOLUBLE (60) Provisional application No. 61/813,835, filed on Apr. LPIDATED LGAND AGENTS 19, 2013, provisional application No. 61/811.249, filed on Apr. 12, 2013. (71) Applicants: TUFTS MEDICAL CENTER, Boston, Publication Classification MA (US); TRUSTEES OF TUFTS COLLEGE, Medford, MA (US) (51) Int. C. C07K 4/47 (2006.01) (72) Inventors: Charles Cohen, Weston, MA (US); C07K 7/06 (2006.01) Krishna Kumar, Cambridge, MA (US); C07K 7/08 (2006.01) Jamie Raudensky Doyle, Newton, MA GOIN33/50 (2006.01) (52) U.S. C. (US); Alan S. Kopin, Wellesley, MA CPC ........ C07K 14/4703 (2013.01); G0IN33/5023 (US) (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); A61 K38/00 (2013.01) (21) Appl. No.: 14/783,489 (57) ABSTRACT (22) PCT Fled: Mar. 13, 2014 The present application provides methods for preparing soluble lipidated ligandagents comprising a ligand entity and (86) PCT NO.: PCT/US2O14/026.662 a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling S371 (c)(1), appropriate selection of components to assemble active (2) Date: Oct. 9, 2015 agents for any given target of interest. Patent Application Publication Feb. 25, 2016 Sheet 1 of 13 US 2016/0052982 A1 hita CKR wM S-C& 8-5 wn S-88 - Sif the saxes ..? s ligard, log(N) Riotse CXR wha S-C8 &S-Sf e S-882.
  • Spatio-Mechanical Epha2/Ephrin-A1 Signaling in Cancer Cells by Qian

    Spatio-Mechanical Epha2/Ephrin-A1 Signaling in Cancer Cells by Qian

    Spatio-mechanical EphA2/ephrin-A1 Signaling in Cancer Cells by Qian Xu A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Biophysics in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Jay T. Groves, Chair Professor John Kuriyan Professor Jan Liphardt Professor Kunxin Luo Spring 2011 Spatio-mechanical EphA2/ephrin-A1 Signaling in Cancer Cells Copyright 2011 By Qian Xu 1 Abstract Spatio-mechanical EphA2/ephrin-A1 Signaling in Cancer Cells by Qian Xu Doctor of Philosophy in Biophysics University of California, Berkeley Professor Jay T. Groves, Chair Communication strategies in nature are an integral part to the survival of multi-cellular organisms. Cell membranes provide the chemical environment in which intercellular signaling begins. The vast complexity of this signaling requires that a relatively conserved set of chemical constituents be able to generate enormous signal diversity. Spatial sorting of signaling molecules within the membrane allows for this diversity. My research uses synthetic lipid membranes, solid-state nanostructures, and high-resolution imaging to study a potentially novel spatio- mechanical regulatory mechanism in the EphA2 signaling pathway. My hypothesis is that the multi-scale organization of the EphA2 receptor in the cell membrane regulates its biochemical function. This hypothesis is motivated by the idea that extracellular mechanical inputs have an important role in intracellular signaling cascades. i 1
  • Epha Kinase Activation Regulates HGF-Induced Epithelial Branching

    Epha Kinase Activation Regulates HGF-Induced Epithelial Branching

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central JCBArticle EphA kinase activation regulates HGF-induced epithelial branching morphogenesis Hui Miao,1 Christian H. Nickel,2 Lloyd G. Cantley,2 Leslie A. Bruggeman,1 Laura N. Bennardo,1 and Bingcheng Wang1 1Rammelkamp Center for Research, MetroHealth Campus, and Department of Pharmacology and Ireland Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44109 2School of Medicine, Yale University, New Haven, CT 06520 ph kinases and their ephrin ligands are widely expressed Ephrin-A1 inhibited basal ERK1/2 mitogen-activated protein in epithelial cells in vitro and in vivo. Our results show kinase activity; however, the ephrin-A1 effect on cell Ethat activation of endogenous EphA kinases in Madin- protrusion was independent of the mitogen-activated Darby canine kidney (MDCK) cells negatively regulates protein kinase pathway. Ephrin-A1 suppressed HGF-induced hepatocyte growth factor/scatter factor (HGF)–induced activation of Rac1 and p21-activated kinase, whereas RhoA branching morphogenesis in collagen gel. Cotreatment with activation was retained, leading to the preservation of stress HGF and ephrin-A1 reduced sprouting of cell protrusions, fibers. Moreover, dominant-negative RhoA or inhibitor of an early step in branching morphogenesis. Moreover, Rho-associated kinase (Y27632) substantially negated the addition of ephrin-A1 after HGF stimulation resulted in inhibitory effects of ephrin-A1. These data suggest that collapse and retraction of preexisting cell protrusions. In interfering with c-Met signaling to Rho GTPases represents a newly developed assay that simulates the localized inter- a major mechanism by which EphA kinase activation inhibits actions between Ephs and ephrins in vivo, immobilized HGF-induced MDCK branching morphogenesis.
  • Epha2 and EGFR: Friends in Life, Partners in Crime

    Epha2 and EGFR: Friends in Life, Partners in Crime

    cancers Review EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents? Mario Cioce 1,* and Vito Michele Fazio 1,2,3,* 1 Laboratory of Molecular Medicine and Biotechnology, Department of Medicine, University Campus Bio-Medico of Rome, 00128 Rome, Italy 2 Laboratory of Oncology, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy 3 Institute of Translational Pharmacology, National Research Council of Italy (CNR), 00133 Rome, Italy * Correspondence: [email protected] (M.C.); [email protected] (V.M.F.) Simple Summary: The Ephrin receptors and their ligands play important roles in organ formation and tissue repair, by orchestrating complex programs of cell adhesion and repulsion, however, this same system plays a role in cancer development In fact, EphA2 levels are higher in tumors vs normal tissue and further increased upon treatment, in vivo and in vitro. Changes in the molecular status of EphA2, of its subcellular localization, the absence of ligand and signals derived from the tumor context unleash the oncogenic role of EphA2 and its broad ability to promote resistance to radiotherapy, chemotherapy and targeted agents, including inhibitors of Epidermal-Growth-Factor- Receptor (EGFR). High levels of EphA2 may reduce response to cetuximab even in RAS wt CRC patients. In this work, we aim to review the current knowledge of the EphA2 function which is crucial for achieving a more effective therapeutic management of tumors resistant to EGFR inhibitors and to many other agents. Abstract: The Eph receptors represent the largest group among Receptor Tyrosine kinase (RTK) Citation: Cioce, M.; Fazio, V.M.
  • SUPPLEMENTARY APPENDIX Exome Sequencing Reveals Heterogeneous Clonal Dynamics in Donor Cell Myeloid Neoplasms After Stem Cell Transplantation

    SUPPLEMENTARY APPENDIX Exome Sequencing Reveals Heterogeneous Clonal Dynamics in Donor Cell Myeloid Neoplasms After Stem Cell Transplantation

    SUPPLEMENTARY APPENDIX Exome sequencing reveals heterogeneous clonal dynamics in donor cell myeloid neoplasms after stem cell transplantation Julia Suárez-González, 1,2 Juan Carlos Triviño, 3 Guiomar Bautista, 4 José Antonio García-Marco, 4 Ángela Figuera, 5 Antonio Balas, 6 José Luis Vicario, 6 Francisco José Ortuño, 7 Raúl Teruel, 7 José María Álamo, 8 Diego Carbonell, 2,9 Cristina Andrés-Zayas, 1,2 Nieves Dorado, 2,9 Gabriela Rodríguez-Macías, 9 Mi Kwon, 2,9 José Luis Díez-Martín, 2,9,10 Carolina Martínez-Laperche 2,9* and Ismael Buño 1,2,9,11* on behalf of the Spanish Group for Hematopoietic Transplantation (GETH) 1Genomics Unit, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM), Madrid; 2Gregorio Marañón Health Research Institute (IiSGM), Madrid; 3Sistemas Genómicos, Valencia; 4Department of Hematology, Puerta de Hierro General University Hospital, Madrid; 5Department of Hematology, La Princesa University Hospital, Madrid; 6Department of Histocompatibility, Madrid Blood Centre, Madrid; 7Department of Hematology and Medical Oncology Unit, IMIB-Arrixaca, Morales Meseguer General University Hospital, Murcia; 8Centro Inmunológico de Alicante - CIALAB, Alicante; 9Department of Hematology, Gregorio Marañón General University Hospital, Madrid; 10 Department of Medicine, School of Medicine, Com - plutense University of Madrid, Madrid and 11 Department of Cell Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain *CM-L and IB contributed equally as co-senior authors. Correspondence:
  • Harnessing the Power of Eph/Ephrin Biosemiotics for Theranostic Applications

    Harnessing the Power of Eph/Ephrin Biosemiotics for Theranostic Applications

    pharmaceuticals Review Harnessing the Power of Eph/ephrin Biosemiotics for Theranostic Applications Robert M. Hughes 1 and Jitka A.I. Virag 2,* 1 Department of Chemistry, East Carolina University, Science and Technology Building, SZ564, East 5th St, Greenville, NC 27858, USA; [email protected] 2 Department of Physiology, Brody School of Medicine, East Carolina University, Warren Life Sciences Building, LSB239, 600 Moye Blvd, Greenville, NC 27834, USA * Correspondence: [email protected] Received: 11 April 2020; Accepted: 27 May 2020; Published: 1 June 2020 Abstract: Comprehensive basic biological knowledge of the Eph/ephrin system in the physiologic setting is needed to facilitate an understanding of its role and the effects of pathological processes on its activity, thereby paving the way for development of prospective therapeutic targets. To this end, this review briefly addresses what is currently known and being investigated in order to highlight the gaps and possible avenues for further investigation to capitalize on their diverse potential. Keywords: Eph/ephrin; receptor tyrosine kinase; therapeutic target; smart drug; nanoparticles; liposomes; exosomes 1. Introduction Detection, transduction and appropriate response behavior of neighboring cells are essential components of optimal communication and the coordinated and integrated function necessary for survival. In a complex system, this is determined by the summative and timely intracellular processing of a myriad of intersecting signals from various distances and directions. The Eph receptors and ephrin ligands are the largest tyrosine kinase (RTK) superfamily, comprised of 22 known members, subdivided into A- and B-subclasses, and are heterogeneously expressed in almost every tissue [1]. These membrane-anchored proteins exhibit unique cell-to-cell communication via bidirectional signaling, which modulates cytoskeletal dynamics and thus cell–cell recognition and motility, making them integral mediators in developmental processes and the maintenance of homeostasis [2,3].
  • The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer Victoria M

    The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer Victoria M

    Published OnlineFirst February 1, 2016; DOI: 10.1158/0008-5472.CAN-15-0847 Cancer Molecular and Cellular Pathobiology Research The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer Victoria M. Youngblood1, Laura C. Kim1, Deanna N. Edwards2, Yoonha Hwang2,3, Pranav R. Santapuram1, Steven M. Stirdivant4, Pengcheng Lu5, Fei Ye5, Dana M. Brantley-Sieders2,6, and Jin Chen1,2,3,6,7 Abstract Dysregulation of receptor tyrosine kinases (RTK) contributes to bolic pathway that generates intermediates for lipogenesis. Phar- cellular transformation and cancer progression by disrupting key macologic inhibition of glutaminase activity reduced tumor metabolic signaling pathways. The EPHA2 RTK is overexpressed growth in both ephrin-A1–depleted and EPHA2-overexpressing þ in aggressive forms of breast cancer, including the HER2 subtype, tumor allografts in vivo. Mechanistically, we show that the and correlates with poor prognosis. However, the role of EPHA2 enhanced proliferation and glutaminolysis in the absence of in tumor metabolism remains unexplored. In this study, we used ephrin-A1 were attributed to increased RhoA-dependent gluta- in vivo and in vitro models of HER2-overexpressing breast cancer to minase activity. EPHA2 depletion or pharmacologic inhibition investigate the mechanisms by which EPHA2 ligand–indepen- of Rho, glutaminase, or fatty acid synthase abrogated the dent signaling promotes tumorigenesis in the absence of its increased lipid content and proliferative effects of ephrin-A1 prototypic ligand, ephrin-A1. We demonstrate that ephrin-A1 knockdown. Together, these findings highlight a novel, unsus- loss leads to upregulated glutamine metabolism and lipid accu- pected connection between the EPHA2/ephrin-A1 signaling axis mulation that enhanced tumor growth.
  • Eph Receptors and Ephrin Ligands: Embryogenesis to Tumorigenesis

    Eph Receptors and Ephrin Ligands: Embryogenesis to Tumorigenesis

    Oncogene (2000) 19, 5614 ± 5619 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Eph receptors and ephrin ligands: embryogenesis to tumorigenesis Vincent C Dodelet1 and Elena B Pasquale*,1 1The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, California, CA 92037, USA Protein tyrosine kinase genes are the largest family of The Eph receptors become phosphorylated at speci®c oncogenes. This is not surprising since tyrosine kinases tyrosine residues in the cytoplasmic domain following are important components of signal transduction path- ligand binding (Figure 1). Phosphorylated motifs serve ways that control cell shape, proliferation, dierentia- as sites of interaction with certain cytoplasmic signaling tion, and migration. At 14 distinct members, the Eph proteins such as non-receptor tyrosine kinases of the kinases constitute the largest family of receptor tyrosine Src and Abl families and the non-receptor phosphotyr- kinases. Although they have been most intensively osine phosphatase LMW ± PTP (low molecular weight studied for their roles in embryonic development, phosphotyrosine phosphatase); the enzymes phospholi- increasing evidence also implicates Eph family proteins pase C g, phosphatidylinositol 3-kinase, and Ras in cancer. This review will address the recent progress in GTPase activating protein; the adaptors SLAP, Grb2, understanding the function of Eph receptors in normal Grb10, and Nck; and SHEP1, a R-Ras- and Rap-1A- development and how disregulation of these functions binding protein (reviewed by Bruckner and Klein, 1998; could promote tumorigenesis. Oncogene (2000) 19, Dodelet et al., 1999; Flanagan and Vanderhaeghen, 5614 ± 5619. 1998; Kalo and Pasquale, 1999).